InMed Pharmaceuticals Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

INM$15.56+17.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

For the Three Months Ended · For the Nine Months Ended
	March 31		March 31
	2024	2023	2024	2023
	$	$	$	$
Sales	1,172,601	1,033,925	3,314,663	1,824,496
Cost of sales	883,143	841,414	2,416,417	1,415,068
Inventory write-down	-	-	263,404	576,772
Gross profit	289,458	192,511	634,842	(167,344)
Operating Expenses
Research and development and patents	656,764	878,303	2,558,648	3,108,312
General and administrative	1,374,095	1,412,727	4,036,784	4,438,083
Amortization and depreciation	54,767	50,689	164,833	148,786
Foreign exchange loss	48,156	2,733	36,717	79,287
Total operating expenses	2,133,782	2,344,452	6,796,982	7,774,468
Other Income (Expense)
Interest and other income	121,458	155,497	424,261	343,881
Loss before income taxes	(1,722,866)	(1,996,444)	(5,737,879)	(7,597,931)
Tax expense	-	(1,500)	-	(11,300)
Net loss for the period	(1,722,866)	(1,997,944)	(5,737,879)	(7,609,231)
Net loss per share for the period
Basic and diluted	(0.18)	(0.60)	(0.82)	(3.53)
Weighted average outstanding common shares
Basic and diluted	9,612,973	3,328,191	6,961,938	2,156,283

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.